Palisade Bio, Inc. - Common Stock PALI 深 沪
已收盘 11-07 16:00:00 美东时间
1.68
+0.020
+1.20%
华盛通- 最 高1.70
- 今 开1.63
- 成交量 401.84万股
- 最 低 1.515
- 昨 收 1.66
- 总市值 1532.03万
- 52周最高 3.30
- 市盈率 静 --
- 换手率 44.07%
- 52周最低 0.53
- 委 比 -40.11%
- 总股本 911.92万
- 历史最高 18405.00
- 量 比 1.05
- 振 幅 11.14%
- 历史最低 0.53
- 每 手 1
- 风险率 0.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
Palisade Bio appoints Sharon Skare, PhD(c), as Vice President, Global Head of Clinical Operations, highlighting her 24+ years of experience in clinical development. The company is advancing PALI-2108 for ulcerative colitis and fibrostenotic Crohn’s disease, with a Phase 2 IND submission planned for H1 2026. PALI-2108 is an orally administered prodrug designed for targeted PDE4 inhibition in the终端 ileum and colon, aiming to maximize efficacy while...
10-28 12:45
Palisade Bio Doses The First Patients In Its Phase 1b Study Of PALI-2108, A First-In-Class Ileocolonic-Targeted PDE4 Inhibitor Prodrug For Fibrostenotic Crohn's Disease—A Condition With No Approved Therapies
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapiesTopline safety, PK, and PD data anticipated in Q1 2026Advances ongoing development of
10-20 20:48
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
Palisade Bio initiates Phase 1b trial of PALI-2108, a novel PDE4 inhibitor prodrug, for fibrostenotic Crohn’s disease (FSCD), a condition with no approved therapies. The study aims to evaluate safety, PK/PD, and tissue-level responses. PALI-2108 is designed for targeted activation in the terminal ileum and colon, aiming to maximize anti-inflammatory and anti-fibrotic effects while minimizing systemic exposure. Topline data expected in Q1 2026, wi...
10-20 12:45
Palisade Bio Cancels Stockholder Meeting Due to Quorum
Palisade Bio ( ($PALI) ) has provided an update. On October 9, 2025, Palisade B...
10-10 05:28
Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut
Steven Cohen's Point72 Asset Management has doubled the S&P 500's three-year return and is investing in this biotech firm...
10-08 23:30
Palisades Goldcorp任命新任首席财务官
以资源行业为核心的加拿大商业银行Palisades Goldcorp（PALI）周五宣布任命杰夫·施蒂伯（Jeff Stieber）为首席财务官，接替巴萨姆...
10-02 23:05
Palisades Goldcorp gets new finance chief
Palisades Goldcorp (TSXV:PALI:CA) appointed Jeff Stieber as the company's CFO, effective immediately. The appointment of Mr. Stieber follows the resignation of Bassam Moubarak from the post. Mr. Stieb...
10-02 16:41
Palisade Bio shares are trading lower after the company priced a $120M public offering of 171.4M shares at $0.70 per share.
Palisade Bio shares are trading lower after the company priced a $120M public o...
10-01 21:24
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock
Palisade Bio, Inc. announced the pricing of an underwritten public offering of 171,440,559 shares of its common stock at $0.70 per share, generating approximately $120 million in gross proceeds. Ladenburg Thalmann & Co. Inc. is the sole book-running manager. The company also granted underwriters a 45-day option to purchase up to an additional 25,714,285 shares. The offering is expected to close on October 2, 2025, subject to customary conditions....
10-01 13:20
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
Palisade Bio's special stockholder meeting on September 18, 2025, was adjourned due to lack of quorum, as fewer than one-third of outstanding shares were present. The meeting will reconvene on September 26, 2025, in a virtual format. The company continues to seek votes for its proposals outlined in the Proxy Statement filed on August 18, 2025. Stockholders of record as of July 28, 2025, are encouraged to vote by September 25, 2025. If insufficien...
09-18 20:05
